机构：[1]Hebei Med Univ, Dept Med Oncol, Hosp 4, Shijiazhuang, Peoples R China临床科室肿瘤内科河北医科大学第四医院[2]Hebei Med Univ, Dept Oncol, Hosp 4, Shijiazhuang, Peoples R China临床科室肿瘤内科河北医科大学第四医院[3]Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China河北医科大学第四医院
第一作者机构：[1]Hebei Med Univ, Dept Med Oncol, Hosp 4, Shijiazhuang, Peoples R China[2]Hebei Med Univ, Dept Oncol, Hosp 4, Shijiazhuang, Peoples R China[3]Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China
推荐引用方式(GB/T 7714)：
He Liyuan,Zuo Jing,Feng Li,et al.Efficacy and prognosis of sequential 2G ALK-TKI in ALK-positive advanced NSCLC after crizotinib resistance: A real-world single-center research[J].JOURNAL OF CLINICAL ONCOLOGY.2022,40(16):doi:10.1200/JCO.2022.40.16_suppl.e21075.
APA：
He, Liyuan,Zuo, Jing,Feng, Li,Fan, Zhisong,Wang, Long...&Wang, Yudong.(2022).Efficacy and prognosis of sequential 2G ALK-TKI in ALK-positive advanced NSCLC after crizotinib resistance: A real-world single-center research.JOURNAL OF CLINICAL ONCOLOGY,40,(16)
MLA：
He, Liyuan,et al."Efficacy and prognosis of sequential 2G ALK-TKI in ALK-positive advanced NSCLC after crizotinib resistance: A real-world single-center research".JOURNAL OF CLINICAL ONCOLOGY 40..16(2022)
医学